Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
2.
Leuk Lymphoma ; 45(10): 2099-104, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15370256

ABSTRACT

Remicade, a chimeric human-murine monoclonal antibody capable of neutralizing tumor necrosis factor alpha was given to 37 low-risk myelodysplastic syndromes (MDS) patients in two cohorts; 5 and 10 mg/kg intravenously every 4 weeks for 4 cycles. Median age was 68 years, 33 had primary MDS, 14 had refractory anemia (RA), 14 RA with ringed sideroblasts, 9 RA with excess blasts. Nine patients stopped therapy prior to completing 4 cycles, 3 from cohort 1 and 6 from cohort 2 and response was evaluated using the International Working Group criteria in 28 patients who completed the 4 cycles. Six patients showed disease progression, 14 had stable disease and 8 showed hematologic responses, 3/15 (20%) in cohort 1 and 5/13 (38%) in cohort 2. Two patients had multi-lineage responses, 2 had > 100% increase in absolute neutrophils, 1 had > 1 gm/dl increase in hemoglobin, 1 had reduction in blasts from 7% to 1%, and 2 had minor cytogenetic responses (> 50% reduction in + 8 and 20q-metaphases respectively). We conclude that Remicade may have a variety of activities in low risk MDS patients, is well tolerated with a high patient compliance, and may be considered for combination therapy in the future.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Myelodysplastic Syndromes/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Aged , Anemia, Refractory , Antibodies, Monoclonal/toxicity , Chromosome Aberrations , Cytogenetic Analysis , Disease Progression , Female , Humans , Infliximab , Male , Myelodysplastic Syndromes/complications , Myelodysplastic Syndromes/genetics , Pancytopenia/drug therapy , Patient Compliance , Pilot Projects , Remission Induction , Treatment Outcome
4.
Leuk Res ; 25(11): 941-54, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11597729

ABSTRACT

We used bone marrow biopsies instead of mononuclear cells to maintain long-term cultures from 103 patients belonging to all five sub-categories of myelodysplastic syndromes (MDS), as well as 12 normal controls. By week 4, 30-50% confluency was reached and could be maintained for up to 12 weeks with 100% confluency. The four prominent cells were fibroblasts, macrophages, endothelial cells and adipocytes. Immunohistochemical and electron microscopic studies provided lineage confirmation. Normal hematopoiesis was well supported by MDS stroma. Neither the FAB nor cytogenetics was co-related with the potency of growth. MDS stroma appears to be both morphologically and functionally normal.


Subject(s)
Bone Marrow Cells/cytology , Myelodysplastic Syndromes/pathology , Adipocytes/cytology , Adult , Aged , Aged, 80 and over , Antigens, CD34/blood , Bone Marrow Cells/ultrastructure , Case-Control Studies , Cell Culture Techniques/methods , Cell Division , Cell Lineage , Coculture Techniques , Cytogenetic Analysis , Endothelium/cytology , Fetal Blood/immunology , Fibroblasts/cytology , Hematopoiesis , Humans , Immunohistochemistry , Macrophages/cytology , Microscopy, Electron , Middle Aged , Myelodysplastic Syndromes/classification , Stromal Cells/cytology
5.
Blood ; 98(4): 958-65, 2001 Aug 15.
Article in English | MEDLINE | ID: mdl-11493439

ABSTRACT

Thalidomide was administered to 83 patients with myelodysplastic syndrome (MDS), starting at 100 mg by mouth daily and increasing to 400 mg as tolerated. Thirty-two patients stopped therapy before 12 weeks (minimum period for response evaluation), and 51 completed 12 weeks of therapy. International Working Group response criteria for MDS were used to evaluate responses. Intent-to-treat (ITT) analysis classified all off-study patients as nonresponders. Off-study patients belonged to a higher risk category (P =.002) and had a higher percentage of blasts in their pretherapy bone marrow than patients who completed 12 weeks of therapy (P =.003). No cytogenetic or complete responses were seen, but 16 patients showed hematologic improvement, with 10 previously transfusion-dependent patients becoming transfusion independent. Responders had lower pretherapy blasts (P =.016), a lower duration of pretherapy platelet transfusions (P =.013), and higher pretherapy platelets (P =.003). Among responders, 9 had refractory anemia (RA); 5 had RA with ringed sideroblasts; and 2 had RA with excess blasts. By ITT analysis, 19% of patients (16 of 83) responded, and when only evaluable patients were analyzed, 31% (16 of 51) responded. It was concluded that thalidomide, as a single agent, is effective in improving cytopenias of some MDS patients, especially those who present without excess blasts. (Blood. 2001;98:958-965)


Subject(s)
Anemia/drug therapy , Blood Transfusion , Myelodysplastic Syndromes/drug therapy , Thalidomide/pharmacology , Aged , Anemia/blood , Anemia/etiology , Blood Cell Count , Bone Marrow/drug effects , Bone Marrow/pathology , Female , Hematopoiesis/drug effects , Hemoglobins/metabolism , Humans , Male , Maximum Tolerated Dose , Myelodysplastic Syndromes/blood , Myelodysplastic Syndromes/complications , Pilot Projects , Thalidomide/toxicity , Treatment Outcome
6.
Br J Haematol ; 115(4): 881-94, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11843822

ABSTRACT

Thirty patients with myelodysplastic syndromes (MDS) were treated with thalidomide at 100 mg/d p.o., increased as tolerated to 400 mg/d for 12 weeks. Levels of apoptosis, macrophage number, microvessel density (MVD), tumour necrosis factor alpha (TNF-alpha), transforming growth factor beta (TGF-beta), interleukin 6 (IL-6), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) were determined in the serum, bone marrow (BM) plasma and BM biopsies before and after therapy. Pretherapy biological characteristics of MDS patients were compared with similar studies performed in 11 normal volunteers. Ten patients demonstrated haematological improvement in the erythroid series, six becoming transfusion independent. Responders had a higher pretherapy platelet count (P < 0.048) and lower BM blasts (P < 0.013). Median time to response was 10 weeks, and four remain in remission beyond a year. Pretherapy MDS BMs showed higher MVD (P < 0.001) and TGF-beta (P < 0.03) and higher serum TNF-alpha (P < 0.008) compared with normal control subjects. After therapy, only BM TGF-beta decreased significantly (P < 0.002). Pretherapy haemoglobin was directly related to serum VEGF (P < 0.001) in responders and inversely related in non-responders (P < 0.05), suggesting the possibility that angiogenesis may be a primary pathology in the former and a consequence of anaemia-induced hypoxia in the latter. We conclude that thalidomide has important clinical and biological effects in at least a subset of MDS patients, but the precise mechanism of its action remains unknown and requires further study including a larger number of patients.


Subject(s)
Cytokines/analysis , Immunosuppressive Agents/therapeutic use , Myelodysplastic Syndromes/drug therapy , Thalidomide/therapeutic use , Aged , Case-Control Studies , Cytokines/blood , Endothelial Growth Factors/blood , Female , Hemoglobins/analysis , Humans , Lymphokines/blood , Male , Myelodysplastic Syndromes/blood , Myelodysplastic Syndromes/immunology , Platelet Count , Remission Induction , Transforming Growth Factor alpha/blood , Transforming Growth Factor beta/analysis , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
7.
J Hematother Stem Cell Res ; 9(2): 247-55, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10813538

ABSTRACT

Serum lipid profiles were obtained in 108 patients with myelodysplastic syndrome (MDS) and compared to 28 healthy volunteers. Serum cholesterol and low-density and high-density lipoproteins (LDL and HDL) were found to be significantly lower in MDS patients than in normals (p = 0.0001, 0.0038 and 0.037, respectively). This difference was significant for all MDS categories. Serum cholesterol and HDL were negatively related to biopsy cellularity (p = 0.001 and 0.0001, respectively), and serum triglycerides were negatively related to labeling index (p = 0.0003). No differences were noted in the lipid profiles of MDS patients with normal versus abnormal karyotypes. However, low-risk MDS patients with abnormal karyotypes had significantly lower triglyceride levels compared with the high-risk patients (p = 0.027), as did low-risk patients with normal cytogenetics (p = 0.015). Serum HDL levels were significantly higher for the low-risk group with normal cytogenetics as well (p = 0.003). We conclude that serum cholesterol, LDL, and HDL are significantly reduced in MDS patients, probably indicating excessive intracellular lipid biosynthesis in the expanding clone. These relatively simple measurements could serve as important prognostic markers and reliable indicators of disease activity in individual patients. Prospective studies to determine their utility as independent variables that guide the need for active therapeutic intervention are warranted.


Subject(s)
Lipids/blood , Myelodysplastic Syndromes/blood , Adult , Aged , Anemia, Refractory/blood , Anemia, Refractory, with Excess of Blasts/blood , Anemia, Sideroblastic/blood , Apoptosis , Cell Division , Cholesterol/blood , Chromosome Aberrations , Cytogenetics , Female , Humans , Leukemia, Myelomonocytic, Chronic/blood , Leukocyte Count , Lipids/chemistry , Lipoproteins, HDL/blood , Lipoproteins, LDL/blood , Male , Middle Aged , Myelodysplastic Syndromes/genetics , Risk Factors , Triglycerides/blood , Tumor Necrosis Factor-alpha/metabolism
8.
Blood ; 95(5): 1580-7, 2000 Mar 01.
Article in English | MEDLINE | ID: mdl-10688811

ABSTRACT

Thirty-five patients with myelodysplastic syndrome (MDS) were registered on protocol MDS 96-02 and were receiving continuous therapy with pentoxifylline 800 mg 3 times a day and ciprofloxacin 500 mg twice a day by mouth; dexamethasone was added to the regimen for the partial responders and the nonresponders after 12 weeks at a dose of 4 mg by mouth every morning for 4 weeks. Amifostine was administered intravenously 3 times a week at 3 dose levels (200 mg/M(2), 300 mg/M(2), and 400 mg/M(2)) to cohorts of 10 patients each. Therapy has been continued for 1 year in responders. Twenty-nine have completed at least 12 weeks of therapy and are available for response evaluation. Of the 21 men and 8 women (median age, 67 years), 20 had refractory anemia (RA), 3 had RA with ringed sideroblasts (RARS), 5 had RA with excess blasts (RAEB), and 1 had chronic myelomonocytic leukemia (CMMoL). Five had secondary MDS. No differences were noted in response rates among the 3 dose levels. Seven patients did not respond at all, and 22 showed an improvement in cytopenias (76%). Three had a triple lineage response, 10 had a double lineage response, and 9 had a single lineage response (8 of 9 in absolute neutrophil count [ANC] and 1 had more than a 50% reduction in packed red blood cell transfusions). Fifteen patients responded only after the addition of dexamethasone, whereas 7 responded before. When examined by lineage, 19 of 22 showed improved ANC, 11 of 22 demonstrated more than 50% reduction in blood transfusions, improved Hb levels, or both, and 7 of 22 showed improvement in platelet counts. Interestingly, the responses were frequently slow to appear, and continued improvement in counts was seen up to 12 months of therapy and beyond. This study supports the feasibility of treating patients with MDS with the unique approach of cytoprotection and anticytokine therapies as well as the principle that prolonged commitment to treatment is desirable when noncytotoxic agents are administered. (Blood. 2000;95:1580-1587)


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Myelodysplastic Syndromes/drug therapy , Palliative Care , Adult , Aged , Aged, 80 and over , Amifostine/administration & dosage , Amifostine/adverse effects , Anorexia/chemically induced , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Blood Cell Count/drug effects , Ciprofloxacin/administration & dosage , Ciprofloxacin/adverse effects , Dexamethasone/administration & dosage , Dexamethasone/adverse effects , Female , Gastrointestinal Diseases/chemically induced , Hematologic Diseases/chemically induced , Humans , Hypotension/chemically induced , Male , Middle Aged , Myelodysplastic Syndromes/mortality , Pentoxifylline/administration & dosage , Pentoxifylline/adverse effects , Treatment Outcome
9.
Leuk Res ; 23(4): 357-64, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10229321

ABSTRACT

Rates of proliferation and apoptosis as well as expression of tumor necrosis factor alpha (TNF-alpha), transforming growth factor beta (TGF-beta) and the number of macrophages were measured in bone marrow (BM) biopsies of 33 patients who presented with hypocellular (cellularity < 30%) myelodysplastic syndromes (MDS). Results showed that 2/3 of the patients had high apoptosis, high cytokine levels and large number of macrophages in their biopsies while 1/3 did not. Apoptosis and TNF-alpha levels were directly related (r = 0.583, P = 0.003, n = 24) as was apoptosis and the degree of anemia (P = 0.033, n = 18). A subgroup of patients with abnormalities of chromosomes 5 or 7 had higher platelets (P = 0.026) and higher apoptosis (P = 0.038) when compared with the rest of the group. Eight patients had no evidence of apoptosis and almost no detectable TNF-alpha in their biopsies. We conclude that within the hypocellular variant of MDS, there may be two distinct sub-groups of patients, one who present with high cytokine-mediated intramedullary apoptosis and the other who may be better characterized as having a stem-cell failure defect since they showed no evidence of apoptosis.


Subject(s)
Myelodysplastic Syndromes/pathology , Adolescent , Aged , Aged, 80 and over , Apoptosis , Cytokines/metabolism , Female , Hematopoietic Stem Cells/pathology , Humans , In Situ Nick-End Labeling , Karyotyping , Macrophages/pathology , Male , Middle Aged , Myelodysplastic Syndromes/genetics , Myelodysplastic Syndromes/metabolism , S Phase
10.
Leuk Lymphoma ; 33(3-4): 281-7, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10221507

ABSTRACT

Rates of proliferation, apoptosis and cytokine expression were measured in bone marrow (BM) biopsies of 164 myelodysplastic syndrome (MDS) patients. There were 107 males and 57 females. Median age was 69 years and 101 had refractory anemia (RA), 17 RA with ringed sideroblasts (RARS), 38 with RA and excess blasts (RAEB) and 8 with RAEB in transformation (RAEB-t). Apoptosis measured by in-situ end labeling (ISEL) was directly related to the number of macrophages (p = 0.028, n = 83). Mean tumor necrosis factor alpha (TNF-alpha) and ISEL positivity were higher in RAEB + RAEB-t patients (p = 0.0554 and p = 0.06 respectively) while hemoglobin was higher for RA + RARS group (p = 0.0472). Patients with high apoptosis had lower white blood cell counts (p = 0.0009), lower percentage of blasts (p = 0.0009) and higher number of macrophages (p = 0.0086). We conclude that measurements of apoptosis, proliferation and cytokine expression provide important biological information which helps to distinguish RA + RARS patients from RAEB + RAEB-t patients, and may be of additive prognostic significance.


Subject(s)
Apoptosis , Cytokines/biosynthesis , Myelodysplastic Syndromes/pathology , Myelodysplastic Syndromes/physiopathology , Adolescent , Adult , Aged , Aged, 80 and over , Anemia/etiology , Biopsy , Bone Marrow Cells/immunology , Bone Marrow Cells/pathology , Cytokines/genetics , DNA Fragmentation , Female , Humans , Macrophages/immunology , Macrophages/pathology , Male , Middle Aged , Myelodysplastic Syndromes/blood , S Phase
11.
Eur J Haematol ; 62(2): 90-4, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10052711

ABSTRACT

Spontaneous intramedullary apoptosis was measured in bone marrow (BM) biopsies of 175 patients with myelodysplastic syndromes (MDS) using in situ end-labeling (ISEL) of fragmented DNA. Two groups of high (n=71) versus low (n =43) levels of apoptosis were identified while 61 patients were ISEL-negative. Semiquantitative assessment of 3 cytokines, the number of macrophages and in vivo labeling indices (LI) were also determined from consecutive sections of the biopsy. Patients with high apoptosis levels tended to have a high LI (p=0.013), more macrophages in their BM biopsies (p=0.006) and higher tumor necrosis factor alpha (TNF-alpha) levels (not significant) compared to patients with no apoptosis. In addition, low risk MDS patients had significantly lower rates of apoptosis (p = 0.047) and lower levels of TNF-alpha (p = 0.055) compared to high-risk MDS patients. We conclude that the genesis of cytopenias in MDS is of multifactorial origin and that cytokine-associated apoptosis clearly identifies a distinct biological subgroup of patients who may benefit selectively by use of anti-cytokine therapies.


Subject(s)
Apoptosis , Bone Marrow/pathology , Myelodysplastic Syndromes/pathology , Tumor Necrosis Factor-alpha/metabolism , Aged , Biomarkers , Female , Humans , Male , Myelodysplastic Syndromes/blood , Myelodysplastic Syndromes/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...